Trial Profile
An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Vascular Interventional Therapy Mediated GPC3-targeted Chimeric Antigen Receptor T Cells in Advanced Hepatocellular Carcinoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti GPC3 chimeric antigen receptor T cell therapy Shanghai Genechem (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shanghai Genechem
- 25 May 2016 New source identified and integrated Chinese Clinical Trial Register (ChiCTR-OIN-16008064 )
- 16 May 2016 New trial record